Netilmicin and amikacin Clinical Observation.docVIP

 PAGE \* MERGEFORMAT 7 Netilmicin and amikacin Clinical Observation Author: Zhou Ying, Sun Shu-ming, Hu Zhixiong 【Abstract】 Objective evaluation of amikacin as the control of netilmicin treatment of lower respiratory tract infection clinical efficacy and safety. Methods A total of 132 cases selected cases, 102 cases were evaluable for efficacy, of which experimental group (netilmicin) and the control group (amikacin) were 52 cases with 50 cases. Safety evaluation of selected cases of 113 patients, the two groups were 56 cases with 57 patients. Drug delivery method for each test group 200mg, day 1, the control group for each 200mg, 2 times a day, two groups of treatment were 7 ~ 14 days. The results of the test group and control group clinical efficacies were 84.61% and 64.00%, bacterial clearance rates were 90.91% and 66.67%, the percentage of susceptible strains, respectively 93.18% and 71.43%, hearing loss rates were 1.79% and 15.79 %. The above results statistically significant difference between the two groups. Conclusion netilmicin for the treatment of lower respiratory tract infections safe and effective antimicrobial agents. 【Key Words】 randomized controlled trials; lower respiratory tract infection; netilmicin; Amikacin; treatment outcome 【Abstract】 Objective To evaluate the efficacy and safety of netilmicin (NET) compared with amikacin (AMK) in the treatment of lower respiratory tract infections. Methods A total of 132 patients enrolled in the study. 102 patients were evaluated for efficacy (NET 52 , AMK 50) and 113 patients were evaluated for safety (NET56, AMK57). NET was administered once a day for 7 ~ 14 days at a daily dose of 200mg and AMK was administered twice a day for 7 ~ 14 days at a daily dose of 400mg.Results The overall clinical efficacy rates of NET and AMK were 84.61% and 64.00%, respectively. The bacteriological clearance rates of NET and AMK were 90.91% and 66.67%, respectively. The bacterial susceptibi